PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för bedaquiline. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

38 hits

Bibliografisk träff 2024-04-25

The importance of heteroresistance and efflux pumps in bedaquiline-resistant Mycobacterium tuberculosis isolates from Iran.

Madadi-Goli N, Ahmadi K, Kamakoli MK, Azizi M, Khanipour S, Dizaji SP, Nasehi M, Siadat SD, Fateh A, Vaziri F.

Ann Clin Microbiol Antimicrob · research-article; journal article · DOI 10.1186/s12941-024-00694-3

Bibliografisk träff 2024-03-13

The exceptions that prove the rule-a historical view of bedaquiline susceptibility.

Miotto P, Cirillo DM, Schön T, Köser CU.

Genome Med · comment; research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/s13073-024-01311-w

Bibliografisk träff 2024-03-01

Bedaquiline Resistance after Effective Treatment of Multidrug-Resistant Tuberculosis, Namibia.

Günther G, Mhuulu L, Diergaardt A, Dreyer V, Moses M, Anyolo K, Ruswa N, Claassens M, Niemann S, Nepolo E.

Emerg Infect Dis · brief-report; journal article · DOI 10.3201/eid3003.240134

Bibliografisk träff 2024-02-12

Identification of genetic determinants of bedaquiline resistance in <i>Mycobacterium tuberculosis</i> in Ural region, Russia.

Umpeleva T, Chetverikova E, Belyaev D, Eremeeva N, Boteva T, Golubeva L, Vakhrusheva D, Vasilieva I.

Microbiol Spectr · research-article; journal article · DOI 10.1128/spectrum.03749-23

Bibliografisk träff 2024-02-01

Genotype-Phenotype Characterization of Serial Mycobacterium tuberculosis Isolates in Bedaquiline-Resistant Tuberculosis.

Brown TS, Tang L, Omar SV, Joseph L, Meintjes G, Maartens G, Wasserman S, Shah NS, Farhat MR, Gandhi NR, Ismail N, Brust JCM, Mathema B.

Clin Infect Dis · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1093/cid/ciad596

Bibliografisk träff 2024-02-01

Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analysis.

Omar S, Whitfield MG, Nolan MB, Ngom JT, Ismail N, Warren RM, Klopper M.

J Antimicrob Chemother · meta-analysis; research support, non-u.s. gov't; research-article; systematic review; journal article · DOI 10.1093/jac/dkad372

Bibliografisk träff 2023-12-19

Mitochondrial dysfunction induced by bedaquiline as an anti-Toxoplasma alternative.

Shi Y, Jiang Y, Qiu H, Hu D, Song X.

Vet Res · research-article; journal article · DOI 10.1186/s13567-023-01252-z

Bibliografisk träff 2023-11-30

Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis.

Labuda SM, Seaworth B, Dasgupta S, Goswami ND, BPaL Accelerated Monitoring Project Team.

Lancet Respir Med · letter · DOI 10.1016/s2213-2600(23)00426-5

Bibliografisk träff 2023-11-28

India's Decision to Deny an Extension of Patent for Bedaquiline: A Public Health Imperative.

Yadav S, Rawal G, Jeyaraman M.

Cureus · review-article; review; journal article · DOI 10.7759/cureus.49542

Bibliografisk träff 2023-11-27

Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosy.

Chauffour A, Lounis N, Andries K, Jarlier V, Veziris N, Aubry A.

PLoS Negl Trop Dis · research support, non-u.s. gov't; research-article; journal article · DOI 10.1371/journal.pntd.0011379

Bibliografisk träff 2023-11-03

Emerging bedaquiline-resistant tuberculosis.

Lange C, Vasiliu A, Mandalakas AM.

Lancet Microbe · article-commentary; comment; research support, non-u.s. gov't; journal article · DOI 10.1016/s2666-5247(23)00321-x

Bibliografisk träff 2023-10-04

Coadministration of bedaquiline and pyrifazimine reduce exposure to toxic metabolite N-desmethyl bedaquiline.

Ding Y, Liu H, Wang F, Fu L, Zhu H, Fu S, Wang N, Zhuang X, Lu Y.

Front Pharmacol · research-article; journal article · DOI 10.3389/fphar.2023.1154780

Bibliografisk träff 2023-08-18

Characterization of stress degradation products of bedaquiline fumarate and bedaquiline by LC-PDA and LC-MS.

Guo K, Wang Y, Ma C.

J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2023.115658

Bibliografisk träff 2023-07-31

Questioning bedaquiline availability.

Holt E.

Lancet Infect Dis · news · DOI 10.1016/s1473-3099(23)00496-6

Bibliografisk träff 2023-01-02

[Extensively drug-resistant tuberculosis treated with bedaquiline].

López Pérez A, Navarro Aznarez H, Pinilla Rello A, Perales Pascual J, Arazo Garcés P.

Rev Esp Quimioter · letter · DOI 10.37201/req/073.2022

Bibliografisk träff 2020-12-09

Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline.

Guo H, Courbon GM, Bueler SA, Mai J, Liu J, Liu J, Rubinstein JL.

Nature · journal article · DOI 10.1038/s41586-020-3004-3

Bibliografisk träff 2015-05-08

Structure of the mycobacterial ATP synthase Fo rotor ring in complex with the anti-TB drug bedaquiline.

Preiss L, Langer JD, Yildiz Ö, Eckhardt-Strelau L, Guillemont JE, Koul A, Meier T.

Sci Adv · research-article; journal article · DOI 10.1126/sciadv.1500106

Bibliografisk träff 2012-12-24

Diarylquinoline compounds induce autophagy-associated cell death by inhibiting the Akt pathway and increasing reactive oxygen species in human nasopharyngeal carcinoma cells.

Cai Y, Wan Z, Sun T, Shi Y, Sun Y, Huang P, Li S, Jiang W.

Oncol Rep · research support, non-u.s. gov't; journal article · DOI 10.3892/or.2012.2207

Bibliografisk träff 2012-10-22

Variations of subunit {varepsilon} of the Mycobacterium tuberculosis F1Fo ATP synthase and a novel model for mechanism of action of the tuberculosis drug TMC207.

Biukovic G, Basak S, Manimekalai MS, Rishikesan S, Roessle M, Dick T, Rao SP, Hunke C, Grüber G.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.01039-12

Bibliografisk träff 2012-09-19

Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment.

Engohang-Ndong J.

Expert Opin Investig Drugs · research support, non-u.s. gov't; review; journal article · DOI 10.1517/13543784.2012.724397

Bibliografisk träff 2012-08-27

In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.

Lechartier B, Hartkoorn RC, Cole ST.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.01476-12

Bibliografisk träff 2012-08-01

New drugs for the treatment of tuberculosis: hope and reality.

Grosset JH, Singer TG, Bishai WR.

Int J Tuberc Lung Dis · review; journal article · DOI 10.5588/ijtld.12.0277

Bibliografisk träff 2012-07-23

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.

Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK.

Lancet · research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(12)61080-0

Bibliografisk träff 2012-05-23

Antituberculosis drug research: a critical overview.

Beena, Rawat DS.

Med Res Rev · research support, non-u.s. gov't; review; journal article · DOI 10.1002/med.21262

Bibliografisk träff 2012-05-21

Novel antibiotics targeting respiratory ATP synthesis in Gram-positive pathogenic bacteria.

Balemans W, Vranckx L, Lounis N, Pop O, Guillemont J, Vergauwen K, Mol S, Gilissen R, Motte M, Lançois D, De Bolle M, Bonroy K, Lill H, Andries K, Bald D, Koul A.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.00273-12

Bibliografisk träff 2012-04-02

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.

Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL.

Antimicrob Agents Chemother · research-article; journal article; research support, n.i.h., extramural · DOI 10.1128/aac.00384-12

Bibliografisk träff 2012-04-01

Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267.

Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C, ACTG 5267 Study Team.

J Acquir Immune Defic Syndr · research-article; clinical trial, phase i; journal article; research support, n.i.h., extramural · DOI 10.1097/qai.0b013e3182410503

Bibliografisk träff 2012-03-05

Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance.

Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1128/aac.06126-11

Bibliografisk träff 2012-02-21

New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure.

Segala E, Sougakoff W, Nevejans-Chauffour A, Jarlier V, Petrella S.

Antimicrob Agents Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1128/aac.06154-11

Bibliografisk träff 2012-02-15

Antituberculosis therapy for 2012 and beyond.

Lauzardo M, Peloquin CA.

Expert Opin Pharmacother · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; research-article; review; journal article; research support, n.i.h., extramural · DOI 10.1517/14656566.2012.657176